Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a Healthcare company (Biotechnology) with a market capitalization of $4.7B. The Maz Rating grades it against the other companies in its sector.
Edgewise Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $43.68, Edgewise Therapeutics, Inc. trades at 4.8x trailing earnings and 2.9x book value, with an EV/EBITDA of 4.0. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of 130.4%, return on invested capital of -11.6% and a free cash flow yield of -4.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 12.30. Over the past 52 weeks the share price ranged from $19.76 to $48.78, with a beta of 0.28.
Edgewise Therapeutics, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Edgewise Therapeutics, Inc. (EWTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 38.6% / 30% · Interest income / Revenue 1649600000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 38.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1649600000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 38.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1649600000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.17% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.1% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 1649600000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.0% / 33.33% · (Cash+Recv) / Total Assets 98.0% / 33.33% · Interest income / Revenue 1649600000.0% / 5% | Fail |
No. As of September 2026, Edgewise Therapeutics, Inc. (EWTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Edgewise Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 1649600000.0% of each dividend: Edgewise Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.